• About Highlight
  • Intro
  • Team & Board
  • Scientific Board
  • Our partners
• Our science
  • Science
  • Pipeline
• News & Media
  • News
  • Media
• Events
• Investors
• Contact

Research & Innovation

• BO-112
• BO-212

Research & Innovation

Explora

Explora

(506) 2437-2200

Lunes - Viernes 9am - 5pm (GMT-6)

O solicita más información con nuestro formulario de contacto

Research & Innovation

• BO-112
• BO-212

Portal

News

Exploring the future of therapies.

News

20 de febrero de 2026

Mercedes Diz appointed Chief Executive Officer of Highlight Therapeutics

Read the full article

News

4 de septiembre de 2025

Buenavista leads €15 million round to further advance immunotherapy

Read the full article

News

13 de abril de 2022

BO-112 shows promising results in patients with immunotherapy-resistant melanoma

Read the full article

News

2 de diciembre de 2021

A new combination that expands the potential of immunotherapy

Read the full article

News

12 de noviembre de 2021

BO-112 shows positive preliminary results in advanced melanoma resistant to immunotherapy

Read the full article

News

2 de marzo de 2021

Highlight Therapeutics and Pivotal launch a new clinical trial with BO-112 in advanced melanoma

Read the full article

News

2 de septiembre de 2020

New collaboration with MSD to advance treatment for immunotherapy-resistant melanoma

Read the full article

News

26 de junio de 2020

BO-112 continues to advance: launch of a study in liver metastases

Read the full article

News

12 de diciembre de 2019

BO-112 debuts at ESMO IO 2019: first clinical data from a Spanish immuno-oncology program

Read the full article

News

10 de diciembre de 2019

MSD and Bioncotech initiate collaboration for a clinical trial in liver metastases

Read the full article